Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24205178 | 0.80 | MAPK1 (0.45) | ALDH1A1SMN1; SMN2TK1 | |
| SCHEMBL11723021 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2TK1LPO | |
| SCHEMBL7549198 | 0.64 | TYMP (0.43) | ALDH1A1SMN1; SMN2TK1 | |
| SCHEMBL24205202 | 0.64 | ALDH1A1 (0.36) | LMNAALDH1A1KDM4ESMN1; SMN2LPO | |
| SCHEMBL2183944 | 0.62 | MAPK1 (0.61) | ALDH1A1SMN1; SMN2TK1 | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.61 | MAPK1 (0.59) | ALDH1A1SMN1; SMN2TK1 | |
| SCHEMBL26040271 | 0.60 | RGS4 (0.34) | ALDH1A1LPO | |
| SCHEMBL24665501 | 0.54 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3175663 | 0.53 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL27403536 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182737-B1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-07-03 | — | — | EP | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2022012799-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | LMNA 1560/4885ALDH1A1 277/4885KDM4E 3198/4885 |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | LMNA 1559/4885ALDH1A1 311/4885KDM4E 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.